



Press Release

Cipla announces the appointment of Mr. Frank Pieters as the Head of European Region and Global Respiratory Business

Mumbai, 3rd July 2012:

Cipla, one of India's leading pharmaceutical companies is delighted to announce the appointment of Mr. Frank Pieters as the Head of European Region and the Global Respiratory Business, effective 3rd July 2012. Prior to joining Cipla, Mr. Frank Pieters served as Sr. Vice President Southern Europe Region in TEVA Pharmaceuticals. He comes on board with over 30 years of experience in the pharmaceutical industry in different senior management positions, with the unique background in respiratory medicine.

Mr. Pieters played a significant role in accelerating the growth of TEVA's Respiratory business globally. He has served as Senior VP Global Biogenerics and Global Respiratory Commercial business for TEVA Pharmaceutical Industries since 2009. He was also a member of the TEVA-Lonza Joint Steering Committee. From 1989 to 2004, Mr. Pieters spearheaded several senior positions at GlaxoSmithKline, last of which was VP and General Manager.

Announcing the appointment of Mr. Frank Pieters, **Dr. Yusuf K Hamied, Chairman and Managing Director, Cipla** said, "Frank brings a wealth of expertise in the respiratory domain. With him at the helm, Cipla would like to capture the huge commercial upside of 30 years experience in Cipla's respiratory medicine; both in emerging and regulated markets. This appointment signals Cipla's strengthening of senior management positions and also illustrates Cipla's desire for senior on-ground talent in overseas markets to build its product portfolio and brand. Apart from global respiratory business, Frank will also spearhead the generics and value-added product portfolio across the European region through strategic alliances."

Mr. Frank Pieters said, "After spending very interesting years both at GSK and TEVA, I'm thrilled to join the Cipla Team, helping to expand both the Respiratory business worldwide and the European Business. Building further on the outstanding capabilities and business network will definitely bring exciting times for the company in these domains."

About Cipla:

Cipla laid foundations for the Indian pharmaceutical industry back in 1935 with the vision to make India self-reliant in healthcare. Over the years Cipla has emerged as one of the most respected names not just in India but worldwide. Its state of the art R&D centre has given the country and the world many firsts. This includes the revolutionary AIDS cocktail for less than a dollar a day. With over 34 manufacturing units across the country, Cipla manufactures over 2000 products in 65 therapies.

With a turnover of over US \$ 1.4 billion, Cipla serves doctors and patients in over 183 countries. It has earned a name for maintaining one global standard across all its products and services. Cipla continues to support, improve and save millions of lives with its high-quality drugs and innovative devices. (www.cipla.com).

With a strong focus in Respiratory medicine, Cipla has the world's widest range of drugs, dosage forms and inhaler devices. It has pioneered innovative drugs and inhalation in India and has given the world many firsts in the management of asthma.

Media Contact:

Jaisingh Balakrishnan| Corporate Communications| Cipla Limited| Mobile: +91-9833836185|